Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
Open Access
- 14 August 2012
- journal article
- review article
- Published by Hindawi Limited in Schizophrenia Research and Treatment
- Vol. 2012, 1-8
Abstract
Clinical and psychosocial deterioration associated with schizophrenia occurs within the first few years following the onset of the illness. Therefore, to improve the long-term prognosis, it is important to provide schizophrenia patients with intensive treatment following their first episode. Relapse is highly associated with partial medication adherence or nonadherence in patients with first-episode schizophrenia. Recent studies suggest that long-acting injectable (LAI) antipsychotics compared with oral antipsychotics are more effective for medication adherence and relapse prevention. Moreover, some clinical guidelines for the treatment of schizophrenia suggested that LAI antipsychotics should be considered when patients are nonadherent “at any stage.” Decreased compliance is a common cause of relapse during the initial stages of the disease. Therefore, LAI antipsychotics should be highly considered when treating patients with first-episode schizophrenia. In the present paper, clinical trial data and current guidelines on the use of LAI antipsychotics for first-episode schizophrenia are discussed as well as the pros and cons of this treatment option.Keywords
This publication has 51 references indexed in Scilit:
- Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset SchizophreniaSchizophrenia Research and Treatment, 2012
- Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off studyHealth and Quality of Life Outcomes, 2012
- Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEuropean Psychiatry, 2011
- A Randomized Controlled Trial of Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia PatientsThe Journal of Clinical Psychiatry, 2009
- Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a cluster randomised controlled trial (FIAT)BMC Psychiatry, 2009
- Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studiesClinical Therapeutics, 2008
- Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging studyMolecular Psychiatry, 2008
- Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic DisordersCNS Drugs, 2008
- Financial incentives for antipsychotic depot medication: ethical issues: Table 1Journal of Medical Ethics, 2007
- First-Episode SchizophreniaDrugs, 2005